BREAKING NEWS: NEW TREATMENT FOR COVID-19? Part-II
As coronavirus in India is took a new turn, Glenmark Pharmaceuticals launched the antiviral medication Favipiravir, under the brand name FabiFlu, for the mild to moderate COVID-19 cases, while Cipla and Hetero have gotten endorsements from the Drug Controller General of India (DCGI) to dispatch Remdesivir under the brand names Cipremi and Covifor individually.
I hope my last blog (click to read) gave you an in-depth understanding of Favipiravir.
Here's the second part of the last blog which focuses on the drug Remdesivir.
Amidst the coronavirus outbreak, Cipla Ltd on June 22, Sunday reported the launch of Cipremi.
The medication Remdesivir has been under the spotlight as a potential treatment for basic cases of novel coronavirus (COVID-19). Globally, it is being examined in the solidarity preliminaries under the World Health Organization (WHO). Ongoing examinations have asserted they have discovered promising outcomes.
Remdesivir is a drug with antiviral properties that was made by a US-based biotechnology organization in 2014, to treat Ebola cases. Remdesivir works against all strains of Ebola. It was likewise used for the treatment of patients of MERS and SARS, both brought about by members of the coronavirus family, however, specialists said it did now show promising outcomes in those days.
Coronaviruses have a single strand RNA as their hereditary material. At the point when the novel coronavirus SARS-CoV2 enters a human cell, a chemical called RdRP enables the virus to reproduce. Remdesivir works by repressing the action of RdRP.
The medication will be accessible in 100 mg vials (injectable) which must be injected intravenously in a clinic setting under the supervision of a healthcare professional. With respect to coronavirus patients, Remdesivir can be injected quickly but must be given once daily for 10 days.
Hetero Group of Companies MD Vamsi Krishna Bandi disclosed to PTI that the drug will be valued in the range of Rs 5,000-6,000 for each dose.
Given the conditions of coronavirus in US, Remdesivir is approved for use under an Emergency Use Authorization (EUA) just for the treatment of patients with suspected or with laboratory-confirmed SARS-CoV-2 contamination and extreme COVID-19.
Remdesivir has shown in vitro and in vivo activity in animal models against the viral pathogens that cause MERS and SARS.
Serious side effects appear to be few. Some patients receiving treatment have experienced headaches, fever, and rapid heartbeats.
I hope you found your daily dose of knowledge through this blog! Do you have any other topics/diseases/ in mind that you would want me to write about? Let me know in the comment section. :)
Click on that FOLLOW button (to the panel on your right) and put in your mail ID to get a notification every time I publish a new blog!
CHECK OUT OTHER BLOGS FROM THIS AUTHOR. THANKYOU!!!
CHECK OUT BLOGS FROM URBANTRENSY